Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance

10X Genomics IncTrade
Roundhill S&P 500 0DTE Covered Call Strategy ETFTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.41. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.

TXGXDTE
Market Cap
$8.55B
Sector
HealthIncome / Options Overlay
52-Week High
$67.29$44.76
52-Week Low
$11.34$36.00
Enterprise Value
$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Roundhill S&P 500 0DTE Covered Call Strategy ETF

XDTE trades at $38.60, down 0.5% on the day, with technical indicators showing bearish momentum as moving averages signal selling pressure. The ETF's weekly dividend strategy has generated significant attention, with recent payouts ranging from $0.09 to $0.26 per share. However, financial ratios remain unavailable, limiting fundamental analysis. Recent news coverage highlights concerns about the sustainability of XDTE's high yield strategy and fee structure compared to alternatives.

The outlook for XDTE appears cautious due to questions about dividend sustainability and competitive fee pressures. While the weekly income strategy attracts yield-seeking investors, structural risks and bearish technical signals suggest limited near-term upside potential. Investors should weigh the high distribution yield against potential total return underperformance in rising markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Roundhill S&P 500 0DTE Covered Call Strategy ETF

XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.

Read more on XDTE